series-b
Stage
1
Investors
About
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, addressing dysregulated growth and hyperactive signaling in rare genetic and age-related diseases. Its lead candidate, AV078, is a first-in-class CNS-penetrant selective inhibitor of mTOR complex 1 (mTORC1) for treating tuberous sclerosis complex (TSC) refractory epilepsy.
Explore Aeovian Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.